Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 96

1.

Efficacy of low-dose imatinib mesylate for cutaneous involvement in systemic sclerosis: a preliminary report of three cases.

Tamaki Z, Asano Y, Hatano M, Yao A, Kawashima T, Tomita M, Kinugawa K, Nagai R, Sato S.

Mod Rheumatol. 2012 Feb;22(1):94-9. doi: 10.1007/s10165-011-0472-1. Epub 2011 Jun 3.

PMID:
21633912
2.

A one-year, phase I/IIa, open-label pilot trial of imatinib mesylate in the treatment of systemic sclerosis-associated active interstitial lung disease.

Khanna D, Saggar R, Mayes MD, Abtin F, Clements PJ, Maranian P, Assassi S, Saggar R, Singh RR, Furst DE.

Arthritis Rheum. 2011 Nov;63(11):3540-6. doi: 10.1002/art.30548.

3.

Prospective, open-label, uncontrolled pilot study to study safety and efficacy of sildenafil in systemic sclerosis-related pulmonary artery hypertension and cutaneous vascular complications.

Kumar U, Sankalp G, Sreenivas V, Kaur S, Misra D.

Rheumatol Int. 2013 Apr;33(4):1047-52. doi: 10.1007/s00296-012-2466-5. Epub 2012 Jul 26. Erratum in: Rheumatol Int. 2013 Apr;33(4):1053. Gokhle, Sankalp S [corrected to Sankalp, Gokhale].

PMID:
22833239
4.

Is imatinib mesylate a promising drug in systemic sclerosis?

van Daele PL, Dik WA, Thio HB, van Hal PT, van Laar JA, Hooijkaas H, van Hagen PM.

Arthritis Rheum. 2008 Aug;58(8):2549-52. doi: 10.1002/art.23648.

5.

Low-dose oral imatinib in the treatment of systemic sclerosis interstitial lung disease unresponsive to cyclophosphamide: a phase II pilot study.

Fraticelli P, Gabrielli B, Pomponio G, Valentini G, Bosello S, Riboldi P, Gerosa M, Faggioli P, Giacomelli R, Del Papa N, Gerli R, Lunardi C, Bombardieri S, Malorni W, Corvetta A, Moroncini G, Gabrielli A; Imatinib in Scleroderma Italian Study Group..

Arthritis Res Ther. 2014 Jul 8;16(4):R144. doi: 10.1186/ar4606.

6.

Imatinib mesylate treatment of nephrogenic systemic fibrosis.

Kay J, High WA.

Arthritis Rheum. 2008 Aug;58(8):2543-8. doi: 10.1002/art.23696.

7.

Imatinib mesylate reduces production of extracellular matrix and prevents development of experimental dermal fibrosis.

Distler JH, Jüngel A, Huber LC, Schulze-Horsel U, Zwerina J, Gay RE, Michel BA, Hauser T, Schett G, Gay S, Distler O.

Arthritis Rheum. 2007 Jan;56(1):311-22.

8.

[A new therapeutic avenue for severe systemic sclerosis: imatinib mesylate].

Taïeb A, Constans J, Mahon FX.

Rev Med Interne. 2008 Mar;29(3):173-5. Epub 2007 Jun 21. French. No abstract available.

PMID:
17597261
9.

Imatinib mesylate in scleroderma-associated diffuse skin fibrosis: a phase II multicentre randomized double-blinded controlled trial.

Prey S, Ezzedine K, Doussau A, Grandoulier AS, Barcat D, Chatelus E, Diot E, Durant C, Hachulla E, de Korwin-Krokowski JD, Kostrzewa E, Quemeneur T, Paul C, Schaeverbeke T, Seneschal J, Solanilla A, Sparsa A, Bouchet S, Lepreux S, Mahon FX, Chene G, Taïeb A.

Br J Dermatol. 2012 Nov;167(5):1138-44. doi: 10.1111/j.1365-2133.2012.11186.x. Epub 2012 Oct 5.

PMID:
23039171
10.

Combination therapy with Bosentan and Sildenafil improves Raynaud's phenomenon and fosters the recovery of microvascular involvement in systemic sclerosis.

Bellando-Randone S, Lepri G, Bruni C, Blagojevic J, Radicati A, Cometi L, De Paulis A, Matucci-Cerinic M, Guiducci S.

Clin Rheumatol. 2016 Jan;35(1):127-32. doi: 10.1007/s10067-015-3119-3. Epub 2015 Dec 3.

PMID:
26631100
11.

SSc in 2011: From mechanisms to medicines.

Mouthon L.

Nat Rev Rheumatol. 2012 Jan 10;8(2):72-4. doi: 10.1038/nrrheum.2011.203.

PMID:
22231235
12.

Low-dose imatinib in the treatment of severe systemic sclerosis: a case series of six Chinese patients and literature review.

Guo L, Chen XX, Gu YY, Zou HJ, Ye S.

Clin Rheumatol. 2012 Sep;31(9):1395-400. doi: 10.1007/s10067-012-2032-2. Epub 2012 Aug 9. Review.

PMID:
22875698
13.

Molecular framework for response to imatinib mesylate in systemic sclerosis.

Chung L, Fiorentino DF, Benbarak MJ, Adler AS, Mariano MM, Paniagua RT, Milano A, Connolly MK, Ratiner BD, Wiskocil RL, Whitfield ML, Chang HY, Robinson WH.

Arthritis Rheum. 2009 Feb;60(2):584-91. doi: 10.1002/art.24221.

14.

Smad1 pathway is activated in systemic sclerosis fibroblasts and is targeted by imatinib mesylate.

Pannu J, Asano Y, Nakerakanti S, Smith E, Jablonska S, Blaszczyk M, ten Dijke P, Trojanowska M.

Arthritis Rheum. 2008 Aug;58(8):2528-37. doi: 10.1002/art.23698.

15.

Bosentan improves skin perfusion of hands in patients with systemic sclerosis with pulmonary arterial hypertension.

Rosato E, Molinaro I, Borghese F, Rossi C, Pisarri S, Salsano F.

J Rheumatol. 2010 Dec;37(12):2531-9. doi: 10.3899/jrheum.100358. Epub 2010 Sep 1.

PMID:
20810512
16.

[Efficacy of beraprost sodium on Raynaud's phenomenon in patients with systemic sclerosis].

Kaburaki J, Kuwana M, Akizuki M, Takano M, Tojo T.

Nihon Rinsho Meneki Gakkai Kaishi. 1995 Feb;18(1):29-35. Japanese.

PMID:
7553036
17.

Imatinib mesylate (Gleevec) in the treatment of diffuse cutaneous systemic sclerosis: results of a 1-year, phase IIa, single-arm, open-label clinical trial.

Spiera RF, Gordon JK, Mersten JN, Magro CM, Mehta M, Wildman HF, Kloiber S, Kirou KA, Lyman S, Crow MK.

Ann Rheum Dis. 2011 Jun;70(6):1003-9. doi: 10.1136/ard.2010.143974. Epub 2011 Mar 11.

18.

Treatment with imatinib results in reduced IL-4-producing T cells, but increased CD4(+) T cells in the broncho-alveolar lavage of patients with systemic sclerosis.

Divekar AA, Khanna D, Abtin F, Maranian P, Saggar R, Saggar R, Furst DE, Singh RR.

Clin Immunol. 2011 Dec;141(3):293-303. doi: 10.1016/j.clim.2011.08.010. Epub 2011 Sep 5.

20.

Low versus high-dose iloprost therapy over 21 days in patients with secondary Raynaud's phenomenon and systemic sclerosis: a randomized, open, single-center study.

Kawald A, Burmester GR, Huscher D, Sunderkötter C, Riemekasten G.

J Rheumatol. 2008 Sep;35(9):1830-7. Epub 2008 Jul 15.

PMID:
18634152

Supplemental Content

Support Center